Three IBD 50 stocks are hitting new highs in the stock market today : Valeant Pharmaceuticals (VRX), Regeneron Pharmaceuticals (REGN) and NetEase (NTES). A Goldman Sachs report issued Thursday includes Valeant in the top 5 hedge fund long positions, along with Actavis (ACT), Apple (AAPL), Facebook (FB) and Microsoft (MSFT). And reports said Wednesday that Valeant is in advanced talks to buy Egyptian drugmaker Amoun Pharma. Valeant climbed 2.2% in
From new product introductions to swiped trade secrets, chipmakers have stolen the spotlight so far this week. But let’s not forget about biotech stocks, five of which are highlighted in IBD’s Screen of the Day, Big Cap Leaders, along with their semiconductor counterparts. The large-cap biotechs include Celgene (CELG), Regeneron Pharmaceuticals (REGN) and Gilead Sciences (GILD) Celgene, which has a highest-possible IBD Composite Rating of 99,
Earnings season is winding down, but there are still top stocks due to report, including drug giant Actavis (ACT), one of several drug stocks reporting earnings that day, including Intrexon (XON), Impax Laboratories (IPXL) and Juno Therapeutics (JUNO). Actavis is on the IBD 50 list of the very best stocks. Three other IBD 50 stocks — Regeneron Pharmaceuticals (REGN), Monster Beverage (MNST) and Autohome (ATHM) dished out results in the latest